DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
I•••••••• C•••••• E••••••• S••
Pharmaceuticals, Biotechnology & Life Sciencesgroup grade Aon a schedule nowsponsor unattributed
Also written as: Biotechnology & Life Sciences; Pharmaceuticals
Principal held
at least $75.5M
sum of BDC pieces, a lower bound
Fair value
$83.8M
93c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
0 equity pieces beside them
Next maturity
Sep 1, 2028
no dated debt inside 24 months
On the tape since
Dec 31, 2021
latest Jun 30, 2026
Events
10
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $75.5M | 93c | S+580 bp PIK 1.00% | Sep 1, 2028 | 1 |
Lenders
every BDC piece at the latest quarter end, largest principal first
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| F• K•• C•••••• C••• | term loan first lien | $75.5M | $83.8M 93c | S+580 bp PIK 1.00% |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $75.5M | $83.8M | 93c | 1 |
| Mar 31, 2026 | 1 | $75.2M | $84.9M | 95c | 1 |
| Dec 31, 2025 | 1 | $75.1M | $87.1M | 97c | 1 |
| Sep 30, 2025 | 1 | $74.8M | $86.4M | 97c | 1 |
All 17 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 1 | $91.1M | $102M | 95c | 1 |
| Mar 31, 2025 | 1 | $90.1M | $92.1M | 87c | 1 |
| Dec 31, 2024 | 1 | $178M | $173M | 83c | 2 |
| Sep 30, 2024 | 1 | $88.9M | $94.4M | 91c | 0 |
| Jun 30, 2024 | 1 | $88.8M | $90.6M | 88c | 0 |
| Mar 31, 2024 | 1 | $88.8M | $92.3M | 90c | 0 |
| Dec 31, 2023 | 1 | $178M | $188M | 91c | 0 |
| Sep 30, 2023 | 1 | $88.8M | $89.8M | 88c | 0 |
| Jun 30, 2023 | 1 | $88.8M | $91.3M | 89c | 0 |
| Mar 31, 2023 | 1 | $88.8M | $94.0M | 92c | 0 |
| Dec 31, 2022 | 1 | $178M | $183M | 89c | 0 |
| Sep 30, 2022 | 1 | $88.8M | $85.6M | 84c | 0 |
| Dec 31, 2021 | 1 | $88.8M | $104M | 103c | 0 |
What changed
- Spread changed (observed)Sep 30, 2025
- Maturity extended (observed)Sep 30, 2025
- Maturity extended (observed)Sep 30, 2025
- Mark recoveredJun 30, 2025
- Spread changed (observed)Mar 31, 2025
Full timeline · 15 eventsShow fewer
- Spread increasedMar 31, 2025
- Marked down across lendersDec 31, 2024
- PIK interest appearsDec 31, 2024
- Marked down (one lender)Dec 31, 2024
- PIK interest appearsDec 31, 2024
- Spread changed (observed)Sep 30, 2024
- Mark recoveredDec 31, 2022
- Marked down across lendersSep 30, 2022
- Marked down (one lender)Sep 30, 2022
- New borrower on a BDC scheduleDec 31, 2021
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- INDUSTRIA CHIMICA EMILIANAderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Pharmaceuticals, Biotechnology & Life Sciencesreportedas one filer wrote it